Chimeric Antigen Receptor – T cell (CAR-T) therapy is one of the most exciting, promising treatment breakthroughs in recent years. Texas Oncology is one of the very few authorized centers in the country to initially provide CAR-T therapy. Learn more about how CAR-T therapy works in this ...
In recent years, ICIs revolutionize the cancer treatment [91]. Research on monoclonal antibodies (mAbs) as inhibitors against the immune checkpoints that include PD-1, CTLA-4, TIGIT, LAG-3, and TIM-3, has undertaken a flurry of breakthroughs [92]. Among them, ipilimumab (anti-CTLA-4 mAb...
Dowd, Rachel
Given the rarity of such therapeutic synergism, little time has been wasted to determine how to best harness the anti-cancer abilities of γδ T cells and n-BP for the treatment and prevention of cancer metastasis. In this chapter we provide an overview of the major breakthroughs of this ...
Cancer immunotherapy has gained attention as the supreme therapeutic modality for the treatment of various malignancies. Adoptive T-cell therapy (ACT) is one of the most distinctive modalities of this therapeutic approach, which seeks to harness the potential of combating cancer cells by using autologo...
TCR-T cell therapy represents a promising advancement in adoptive immunotherapy for cancer treatment. Despite its potential, the development and preclinical testing of TCR-T cells face significant challenges. This review provides a structured overview of
The product of Fosun Kite Biotechnology Co., Ltd., jointly established by Shanghai Fosun Pharmaceutical (Group) Co., Ltd. and Kite Pharma of the United States (trade name: Yikaida®) for the treatment of adult large B-cell lymphoma (r/r LBCL) ("this ne
April 17, 2023. Other CB-020, an Induced Pluripotent Stem Cell (iPSC)-Derived Allogeneic CAR-NK Cell Therapy, Engineered for Enhanced Activity Against Solid Tumors 12th AACR-JCA Joint Conference: Breakthroughs in Cancer Research – Translating Knowledge into Practice. December 10-14, 2022....
Despite the high therapeutic response achieved with B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapy in relapsed and refractory multiple myeloma (R/R MM), primary resistance and relapse exist with single-target immunotherapy. Here, we design bispecific BC19 ...
In an interview with Targeted Oncology, Erika Hamilton, MD, discussed emerging endocrine therapies that are advancing breast cancer treatment. Read More Breakthroughs and Challenges in BCL-2 Inhibitor Therapy for CLL Treatment Jordyn Sava October 24th 2024 ...